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Background: Activating KRAS mutations are reported in up to 90% of pancreatic cancers.  
Refametinib potently inhibits MEK1/2, part of the MAPK signalling pathway.  This 
phase I/II study evaluated the safety and efficacy of refametinib plus gemcitabine in patients 
with advanced pancreatic cancer. 
Methods: Phase I comprised dose escalation, followed by phase II expansion.  Refametinib 
and gemcitabine plasma levels were analysed for pharmacokinetics.  KRAS mutational status 
was determined from circulating tumour DNA. 
Results: Ninety patients overall received treatment.  The maximum tolerated dose was 
refametinib 50 mg twice daily plus standard gemcitabine (1000 mg/m2 weekly).  The 
combination was well tolerated, with no pharmacokinetic interaction.  Treatment-emergent 
toxicities included thrombocytopenia, fatigue, anaemia and oedema.  The objective response 
rate was 23% and the disease control rate was 73%.  Overall response rate, disease control 
rate, progression-free survival and overall survival were higher in patients without detectable 
KRAS mutations (48% vs 28%, 81% vs 69%, 8.8 vs 5.3 months and 18.2 vs 6.6 months, 
respectively). 
Conclusion: Refametinib plus gemcitabine was well tolerated, with a promising objective 
response rate, an acceptable safety profile and no pharmacokinetic interaction.  There was a 
trend towards improved outcomes in patients without detectable KRAS mutations that 
deserves future investigation. 
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Pancreatic cancer is among the leading causes of cancer-related mortality worldwide (Ferlay 
et al, 2013), and activating KRAS mutations are reported in up to 90% of pancreatic cancers 
(Kanda et al, 2012; Morris et al, 2010).  Gemcitabine monotherapy has long been the 
standard of care for advanced pancreatic cancer and still represents an option (along with the 
oxaliplatin, irinotecan, fluorouracil and leucovorin regimen, and gemcitabine plus albumin-
bound paclitaxel) for first-line therapy in metastatic or locally advanced, unresectable disease 
(Conroy et al, 2011; National Comprehensive Cancer Network 2014; Von Hoff et al, 2013).  
However, the survival improvement with gemcitabine monotherapy is modest (Burris et al, 
1997).  Previous phase II and III trials of gemcitabine combined with other cytotoxic agents 
have shown acceptable safety but inconsistent survival improvement versus monotherapy 
(Cunningham et al, 2009; Goncalves et al, 2012; Herrmann et al, 2007; Moore et al, 2007; 
Nakai et al, 2012).  The promising activity of cytotoxic combinations has also been 
associated with high toxicity (Conroy et al, 2011; Von Hoff et al, 2013). 
Refametinib (BAY 86-9766; Bayer Pharma AG, Berlin, Germany) is an orally available, 
potent, selective, allosteric (non-adenosine triphosphate competitive) inhibitor of MEK1/2 
(Iverson et al, 2009).  Refametinib has demonstrated both single-agent activity (Puehler et al, 
2010) and synergistic activity in combination with gemcitabine (Schmieder et al, 2011) in 
preclinical models of pancreatic cancer. 
A single-arm, open-label, phase I/II study (NCT01251640) evaluated the safety and efficacy 
of refametinib plus gemcitabine in patients with advanced pancreatic cancer eligible for 
first-line gemcitabine.  Phase I investigated the safety, tolerability and pharmacokinetics of 
the combination; phase II evaluated the efficacy, safety and biomarker analysis of the 
recommended phase II dose. 
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METHODS 
The study protocol and all protocol amendments were reviewed and approved by independent 
ethics committees and institutional review boards for each study site before the start of the 
study and before implementation of the amendments.  This study was conducted in 
accordance with the Declaration of Helsinki and the International Conference on 
Harmonization guideline E6 Good Clinical Practice.  All patients provided written, informed 
consent before participation. 
Study design.  This open-label, non-randomised, multicentre study comprised two phases: 
phase I evaluated three dose levels to determine the maximum tolerated dose and 
recommended phase II dose of refametinib plus gemcitabine; phase II evaluated the efficacy, 
safety and biomarker analysis of the recommended phase II dose.  The primary outcome 
measure in phase II was objective response rate (ORR; confirmed complete response and 
confirmed partial response) per independent radiological review.  Secondary outcome 
measures included disease control rate (complete response, partial response and stable 
disease), progression-free survival (PFS), overall survival (OS), toxicity and determination of 
KRAS mutational status (wild type or mutant).  Additional secondary measures were pre-
planned correlation of KRAS mutational status with response and survival, and analysis of 
biomarkers relevant to RAS pathway activation or to pathways known to influence activity of 
RAS-RAF-dependent signal transduction. 
Patients received standard intravenous gemcitabine 1000 mg/m2 weekly on day 1; continuous 
treatment with oral refametinib twice daily began on day 2.  Patients received refametinib 
plus gemcitabine for 7 out of 8 weeks (cycle 1), then 3 out of 4 weeks in subsequent cycles.  
Enrolment of up to 18 patients in phase I was planned.  Dose escalation followed a 3+3 
design.  If no dose-limiting toxicity was seen within the first three patients at the starting dose 
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level (refametinib 30 mg twice daily plus standard gemcitabine) and within the first 4 weeks 
of treatment, the next highest dose level (refametinib 50 mg twice daily plus standard 
gemcitabine) was to be opened immediately.  All three patients enrolled at the starting dose 
level were to continue treatment until they had received a full 8 weeks of therapy.  If a dose-
limiting toxicity occurred within the first three patients at the starting dose level and after the 
first 4 weeks of treatment, further recruitment to the higher dose cohort was to be paused and 
three additional patients were to be enrolled to the starting dose cohort.  If no dose-limiting 
toxicities were observed in these additional three patients within 4 weeks of treatment, then 
enrolment to the higher dose level continued.  If two or more patients out of a maximum of 
six patients showed dose-limiting toxicities at the starting dose level within cycle 1, the next 
lowest dose level would be investigated.  The maximum tolerated dose was the highest dose 
level at which no more than one patient out of six experienced a dose-limiting toxicity.  
Following identification of the maximum tolerated dose, the Data Monitoring Committee was 
to be involved in the definition of the recommended phase II dose. 
Protocol-defined dose-limiting toxicities as defined by the National Cancer Institute Common 
Terminology Criteria for Adverse Events version 4.0 included: grade 4 anaemia; grade 4 
neutropenia lasting more than 10 days; grade 3 or 4 neutropenia with fever greater than 38ºC; 
thrombocytopenia or grade 3 or 4 thrombocytopenia associated with serious bleeding; signs 
of serious bleeding; grade 3 or higher non-haematological toxicity; grade 3 or higher 
diarrhoea if refractory to maximal anti-diarrhoeal therapy; grade 3 skin toxicity for more than 
2 weeks with maximum supportive treatment; grade 4 skin toxicity (with subsequent removal 
from the study); missing more than 14 days of consecutive treatment; and increase in 
aspartate aminotransferase or alanine aminotransferase from grade 1 to grades 2–4 or from 
grade 2 (in patients with liver metastases) to grade 3 or 4 in the case of second occurrence 
after a first recovery to baseline level taking more than 14 days, or a third occurrence. 
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In phase II, treatment with refametinib at the recommended phase II dose, plus standard 
gemcitabine 1000 mg/m2 weekly, began on cycle 1, day 1.  Treatment continued until 
progressive disease, unacceptable toxicity or other discontinuation criteria were met, as 
follows: initiation of a new anti-cancer regimen; development of a second malignancy; 
deterioration of Eastern Cooperative Oncology Group performance status to 4 or more; 
increased aspartate aminotransferase or alanine transaminase from grade 1 to grades 2–4 or 
from grade 2 (in patients with liver metastases) to grade 3 or 4 in the case of second 
occurrence after a first recovery to baseline level taking more than 14 days, or a third 
occurrence; at the patient’s request; if continuation would be harmful to the patient’s health 
(as determined by the investigator); substantial non-compliance with study requirements; 
development of any intercurrent illness that may affect clinical status assessment or study 
end points; positive serum pregnancy test; use of illicit drugs or other substances that may 
contribute to toxicity; interruption in study drug administration because of drug-related 
toxicities for more than 22 days and/or delay of more than 22 days for gemcitabine; or if 
more dose reductions were required than allowed according to protocol. 
Eligibility.  Patients were eligible if aged 18 years or older and with histologically or 
cytologically confirmed, locally advanced or metastatic pancreatic adenocarcinoma not 
amenable to curative surgery or radiotherapy.  Other eligibility criteria included: life 
expectancy of 12 weeks or more; at least one unidimensional lesion measurable by computed 
tomography or magnetic resonance imaging (Response Evaluation Criteria in Solid Tumors 
[RECIST] version 1.1); resolution of all acute toxic effects of any prior local treatment to 
National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 
grade 1 or 0; Eastern Cooperative Oncology Group performance status of 2 or under; 
adequate bone marrow, hepatic and renal function; and normal cardiac function as estimated 
by echocardiography. 
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Assessments.  Screening included demographics and baseline characteristics, 
echocardiography, ophthalmic examination, plasma and tumour biopsy for genotyping and 
biomarker analysis, and tumour evaluation (blinded) by computed tomography or magnetic 
resonance imaging (RECIST version 1.1).  In phase I, serial blood samples for 
pharmacokinetic analysis of gemcitabine and refametinib and the respective inactive 
metabolites difluorodeoxyuridine and M-17 were collected up to 24 hours post-infusion at 
cycle 1, days 1 and 22, and up to 8 hours post-dose at cycle 1, days 21 and 22.  Tumour 
assessments were performed every 8 weeks during treatment until progressive disease or the 
end of treatment.  Confirmatory scans were performed 4 or more weeks after an objective 
tumour response (complete response or partial response) was documented.  Safety (changes 
in laboratory values, vital signs, electrocardiogram and physical examination) was assessed at 
screening, at cycle 1, day 1 and weekly thereafter.  Adverse events (AEs) and concomitant 
medications were assessed continuously from screening onwards.  Following the end of 
treatment, patients entered a 30-day safety follow-up including AE documentation.  Survival 
follow-up was performed monthly up to 8 months after the first treatment of the last patient. 
Pharmacokinetic assessments.  Plasma concentrations of all analytes were measured using 
fully validated high-pressure liquid chromatography with mass spectrometric detection, and 
pharmacokinetic parameters were calculated by non-compartmental analysis using 
WinNonlin® (Version 4.1; Pharsight Corporation, Princeton, NJ, USA). 
Biomarker studies.  Circulating tumour DNA in plasma was analysed for KRAS mutational 
status by beads, emulsions, amplification and magnetics (BEAMing) technology (Covance 
Inc., Princeton, NJ, USA), with an assay cut-off of 0.02% mutant allele for positivity.  
Circulating microRNA from plasma was analysed by quantitative polymerase chain reaction 
using a human microRNA panel (Exiqon, Woburn, MA, USA).  Tumour biopsies were 
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collected where available, as freshly frozen or formalin-fixed and paraffin-embedded.  
Histological analysis comprised haematoxylin and eosin staining and Ki67 immunolabelling.  
Targeted archival tumour gene next-generation sequencing was performed using the 
FoundationOne® panel (Foundation Medicine, Cambridge, MA, USA).  Gene expression was 
analysed using RNA isolated from tumour biopsy samples using the Ovation® formalin-fixed 
and paraffin-embedded circulating DNA synthesis kit (NuGen, San Carlos, CA, USA), and 
RNA sequencing was performed using an Ion Proton™ System (Life Technologies, Grand 
Island, NY, USA).  Reads were mapped to hg19 using TopHat2 (Kim et al, 2013) with 
Bowtie2 (Langmead and Salzberg 2012).  Gene-level read counts and reads per kilobase of 
transcript per million values were calculated with Expressionist® Refiner Genome (Genedata, 
Lexington, MA, USA). 
Statistical analysis.  Phase I data were analysed descriptively.  The primary efficacy end 
point in phase II tested the null hypothesis that the overall response rate would be ≤7% on the 
α-level of 12.5% using a one-sided binomial test; assuming a true overall response rate of 
17% under study treatment, exactly 60 patients treated at the recommended phase II dose 
were required to be analysed for efficacy for a power of 90% (primary analysis set).  The null 
hypothesis was to be rejected if seven or more patients in the primary analysis set 
experienced confirmed complete response or confirmed partial response.  Other secondary 
efficacy end points in phase II were analysed descriptively; corresponding P values are not 
confirmatory.  Descriptive statistics and frequency tables were used for safety analysis for all 
patients who received at least one dose of study treatment. 
RESULTS 
Baseline demographics and disease characteristics.  Of the 24 patients enrolled in phase I, 
20 were treated and evaluable for safety assessment (Supplementary Figure S1A).  Ten 
10 
patients were assigned to dose level 1 (refametinib 30 mg twice daily) and 10 to dose level 2 
(refametinib 50 mg twice daily).  In phase II, 107 patients were enrolled; 80 were treated and 
evaluable for safety assessment (Supplementary Figure S1B), of whom 10 were originally 
enrolled at dose level 2 in phase I and are therefore accounted for twice.  Overall, 55.6% of 
patients were male and the median age was 63 years (Table 1).  Most patients (85.6%) had 
metastatic disease. 
In phase II, of the 60 patients centrally evaluated for response (primary analysis set; 
Supplementary Figure S1B), 39 (65%) had KRAS mutations, as determined from circulating 
tumour DNA.  Frequently observed KRAS mutations included G12D, G12V and G12R; 
mutations in codons 38 or 436 were not observed.  Molecular tumour characterisation was 
performed in 23 out of 30 archival samples (77%) with sufficient tumour content.  Tumour 
exome sequencing revealed KRAS mutations (G12D, G12R, G12V, Q61H, Q61R, A59G) in 
15 out of 16 patient samples containing sufficient DNA (Supplementary Figure S2).  
Frequent co-occurring somatic mutations or amplifications in patients with KRAS mutations 
included TP53 (14 out of 15 [93%]), CDKN2A (5 out of 15 [33%]), C-MYC (4 out of 15 
[27%]) and KAT6A (2 out of 15 [13%]).  One patient with stable disease and low Ki67 H-
score had two co-existing KRAS mutations (A59G, Q61R).  Discordance was observed in 
KRAS mutational status, as determined by BEAMing technology, in three samples. 
Nineteen samples with sufficient tumour content had sufficient RNA for analysis of gene 
expression.  Messenger RNA expression data for all genes and for genes with published 
KRAS pathway signatures (Loboda et al, 2010) were tested for correlation with response to 
treatment; visual inspection of principal component analysis and hierarchical clustering 
results showed no obvious correlation (data not shown; no statistical analysis was performed 
because of the small sample number).  Correlation between copy number alteration and 
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messenger RNA expression level was investigated for genes with copy number alteration in 
more than one patient, and expression of C-MYC and KAT6A correlated with gene 
amplification (Supplementary Figure S3). 
MicroRNA expression data were generated from baseline plasma samples.  No individual 
difference in microRNA was observed for KRAS mutational status, response to treatment, or 
treatment (data not shown).  An association between expression level and KRAS mutational 
status was observed for miR-96-5-p, miR-214-3p and miR-877 (Supplementary Figure S4).  
The false discovery rate for each analysis was 0.35. 
Exposure and safety.  During phase I, treatment was tolerated at dose level 2 (refametinib 
50 mg twice daily plus standard gemcitabine), which was declared the maximum tolerated 
dose and recommended phase II dose.  During phase I, one patient in the 30 mg cohort 
experienced grade 3 deterioration of general status (dose-limiting toxicity), which led to dose 
interruption, remained unresolved and was considered unrelated to treatment.  This patient 
subsequently experienced grade 5 steatohepatitis which was deemed treatment-related 
(gemcitabine); a relationship to refametinib could not be excluded.  One patient in the 50 mg 
cohort experienced grade 3 pneumonitis (dose-limiting toxicity), considered treatment-
related, leading to dose interruption and study withdrawal.  In phase I, four patients from each 
dose level were not evaluable for dose-limiting toxicities because they had not reached the 
end of one cycle of treatment or had received too low a dose of treatment. 
In phase II, the mean daily dose of refametinib was 88 mg overall (range: 52.7–100; relative 
dose intensity: 88%); 66% of patients (53 out of 80) received an average dose of 81–100 mg 
daily.  Mean refametinib treatment duration, excluding interruptions, was 14.7 weeks (range: 
0.9–51.3).  The mean weekly gemcitabine dose was 895.6 mg/m2 (range: 500–1000; relative 
dose intensity: 90%); 95% of patients (76 out of 80) received 751–1000 mg/m2 per week.  
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The mean gemcitabine treatment duration, excluding interruptions, was 11.6 weeks (range: 
1–37). 
The main reasons for study discontinuation in phase II were AEs not associated with 
progressive disease (39%) or radiological progression (33%) (Supplementary Table S1).  All 
patients experienced at least one treatment-emergent AE; most experienced at least one grade 
3 (49%) or grade 4 (23%) treatment-emergent AE.  The most common grade 3 or 4 
treatment-emergent AE was neutropenia (39%; 14% grade 4).  Overall, 66% of patients 
experienced at least one serious AE, considered refametinib-related in 24% of patients and 
gemcitabine-related in 26% of patients.  No grade 5 AEs were considered refametinib-related, 
although one patient (1.3%) had a grade 5 AE considered gemcitabine-related.  Frequent 
treatment-emergent AEs, occurring in ≥20% of patients, are shown in Table 2.  In phase II, 
five patients had pneumonitis (two each at grades 2 and 3, respectively, and one at grade 4), 
in addition to two patients in phase I (one at grade 2 and one at grade 3 [dose-limiting 
toxicity]). 
Pharmacokinetics.  In phase I, following multiple-dose oral administration, refametinib was 
well absorbed at both dose levels (30 mg twice daily and 50 mg twice daily), with 
comparable exposure without (cycle 1, day 21) and with (cycle 1, day 22) gemcitabine 
(Supplementary Figure S5A).  Refametinib and metabolite M-17 pharmacokinetic parameters 
were generally comparable with historical data in patients with other cancer types (Weekes et 
al, 2013) (Supplementary Table S2).  Gemcitabine exposure was comparable when 
administered without (cycle 1, day 1) and with (cycle 1, day 22) refametinib (Supplementary 
Figure S5B).  The pharmacokinetic parameters of gemcitabine and metabolite 
difluorodeoxyuridine are shown in Supplementary Table S3. 
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Efficacy.  Of the 60 patients evaluated for response by independent radiological review, none 
had confirmed complete response and 14 (23%) had confirmed partial response, giving an 
ORR of 23%; the disease control rate was 73% (Table 3).  The null hypothesis of ORR ≤7% 
could thus be rejected. Seven patients had unconfirmed partial response (12%) and no 
patients had unconfirmed complete response. 
Median PFS was 6.3 months and median OS was 8.9 months (Figure 1). 
Response by KRAS mutational status.  Of the 60 patients evaluated for response by 
independent radiological review and for KRAS mutational status in circulating tumour DNA, 
KRAS mutations were detected in 39 (65%).  Of these patients, 11 (28%) had partial response 
(including unconfirmed partial response) and 16 (41%) had stable disease; the disease control 
rate was 69% (27 out of 39).  For patients without detectable KRAS mutations, 10 (48%) had 
partial response (including unconfirmed partial response) and seven (33%) had stable disease; 
the disease control rate was 81% (17 out of 21).  KRAS wild-type allele frequency tended to 
correlate with better tumour response (Figure 2). 
A greater proportion of patients without detectable KRAS mutations (11 out of 20 [55%]) 
showed best change in target lesion size ≥30% compared with patients with detectable KRAS 
mutations (13 out of 31 [43%]; blinded assessment) (Figure 3A). 
Median PFS was 5.3 months and 8.8 months (Figure 3B), and median OS was 6.6 months 
and 18.2 months (Figure 3C), for patients with and without detectable KRAS mutations, 
respectively. 
Of the 54 patients in the primary analysis set evaluable for change in serum level of 
carbohydrate antigen 19-9 from baseline, 29 showed a ≥50% decrease (Supplementary 
Figure S6), which did not appear to be associated with KRAS status.  However, wild-type 
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KRAS was associated with lower serum carbohydrate antigen 19-9 at baseline (P=0.0236) and 
at cycle 1, day 29 (P=0.0154) (Supplementary Figure S7). 
DISCUSSION 
This phase I/II study determined the maximum tolerated dose of refametinib plus gemcitabine 
and evaluated the efficacy and tolerability of the combination in patients with unresectable, 
locally advanced or metastatic pancreatic cancer, for whom gemcitabine is indicated as first-
line treatment. 
The maximum tolerated dose in phase I was identified to be refametinib 50 mg twice daily 
plus standard gemcitabine, consistent with historical refametinib monotherapy data (Weekes 
et al, 2013).  The combination appeared generally feasible, with the most frequent AEs being 
grade 1 or 2.  However, the incidence of grade 3 or 4 neutropenia in phase II (39%) was 
higher than in previous reports of gemcitabine in this patient population (Conroy et al, 2011; 
Cunningham et al, 2009; Herrmann et al, 2007; Moore et al, 2007).  In total, seven patients 
developed pneumonitis, a known toxicity of gemcitabine (Barlési et al, 2004), although it 
remains possible that adding a MEK inhibitor may increase the incidence of pneumonitis, as 
seen in the phase II study of trametinib and gemcitabine (7 out of 80 cases vs 2 out of 80 
cases in the gemcitabine group) (Infante et al, 2014). 
The primary efficacy end point in phase II was reached, with an ORR of 23% for the 
refametinib plus gemcitabine combination; more than twice as high as historical reports of 
gemcitabine monotherapy (range: 5.4–10.5%) (Burris et al, 1997; Nakai et al, 2012; 
Rothenberg et al, 1996).  The overall disease control rate was consistent with historical 
reports of gemcitabine monotherapy (73% vs 29.8–47.2%) (Burris et al, 1997; Nakai et al, 
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2012; Rothenberg et al, 1996).  Baseline demographics and disease characteristics were 
broadly similar to those seen in previous trials (Nakai et al, 2012; Rothenberg et al, 1996). 
Response, PFS and OS were similar to those reported for albumin-bound paclitaxel plus 
gemcitabine (Von Hoff et al, 2013).  Partial response and OS were slightly lower than 
reported for the oxaliplatin, irinotecan, fluorouracil and leucovorin regimen, although PFS 
was similar (Conroy et al, 2011).  ORR and OS were also similar to those recently reported 
for the combination of trametinib and gemcitabine (ORR: 22%; OS: 8.4 months), along with 
the proportion of patients with detectable KRAS mutations (72%) (Infante et al, 2014).  In the 
trametinib and gemcitabine study, OS was greater with trametinib and gemcitabine than with 
gemcitabine and placebo in patients with mutant KRAS (n = 103; 8.3 vs 6.7 months, 
respectively) and those with wild-type KRAS (n = 40; 8.6 vs 5.9 months, respectively).  In our 
study, median OS was also greater in patients without detectable KRAS mutations (18 vs 6.6 
months, respectively), as were median PFS and ORR (8.8 vs 5.3 months and 48% vs 28%, 
respectively). 
The proportion of patients with detectable KRAS mutations as determined from circulating 
tumour DNA was similar to that in a previous study in pancreatic cancer (62.6%) (Kinugasa 
et al, 2015).  In the latter study, OS was greater in patients with wild-type versus mutant 
KRAS (413 vs 276 days, respectively), suggesting a negative prognostic role for KRAS 
mutations detected in circulating tumour DNA. 
Nevertheless, the predictive or prognostic role of KRAS following first-line gemcitabine-
based therapy in pancreatic cancer remains unclear.  Retrospective analysis of first-line 
gemcitabine-based therapy revealed a lower ORR in patients with mutant KRAS compared 
with wild-type KRAS (11% vs 26%, respectively) (Kim et al, 2011).  Subgroup analysis 
revealed longer OS with gemcitabine and erlotinib in patients with wild-type KRAS (9.7 vs 
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5.2 months), with no OS difference between KRAS mutational subgroups treated with other 
gemcitabine-based regimens (7.0 vs 7.0 months) (Kim et al, 2011).  Conversely, subgroup 
analysis of a phase III study (Moore et al, 2007) reported similar OS in patients treated with 
gemcitabine and erlotinib irrespective of KRAS mutational status (6.1 vs 6.0 months in wild-
type and mutant, respectively), while the mutant KRAS subgroup appeared to have greater 
benefit from gemcitabine monotherapy compared with the wild-type subgroup (7.4 vs 4.5 
months, respectively) (da Cunha Santos et al, 2010). 
Results from serum carbohydrate antigen 19-9 levels in both patient subsets were ambiguous 
and do not allow for firm conclusions.  A negative impact of KRAS mutations and high serum 
carbohydrate antigen 19-9 levels on OS has been reported (Ogura et al, 2013). 
C-MYC amplification was prevalent in mutant KRAS tumours, consistent with previous 
observations, suggesting C-MYC pathway activation in these patients (Birnbaum et al, 2011).  
These data suggest that targeting C-MYC pathways may provide an alternative therapeutic 
strategy in the treatment of pancreatic adenocarcinoma (Lin et al, 2014). 
KRAS mutational status also tended to correlate with miR-96-5 and miR-214-3 expression, 
roles for which have been described as a tumour suppressor in pancreatic adenocarcinoma 
(Yu et al, 2010) and in the regulation of growth and invasion of stem-like cells in a 
hepatocellular carcinoma model (Xia et al, 2012), respectively.  However, the significance 
level must be interpreted with caution because of the sample size analysed (800 microRNA 
species), the high false discovery rate and the lack of corrections for multiple comparisons.  
Although preliminary, these data may support a role for circulating microRNAs as 
biomarkers of disease aggressiveness, warranting further investigation. 
Although concordance between the mutational status in tumour specimens and circulating 
tumour DNA is generally very high, discordance between the mutational status in tumour and 
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circulating tumour DNA from fresh plasma may occur and deserves further investigation 
(Higgins et al, 2012; Ignatiadis et al, 2015; Infante et al, 2014).  Discordance was observed 
here in three samples between KRAS mutational status as determined by exome sequencing of 
tumour biopsies and BEAMing technology of fresh plasma.  Although BEAMing technology 
is highly sensitive (Li et al, 2006), sensitivity was not formally tested and false negatives 
could not be conclusively excluded in this small sample. 
Refametinib is metabolised by liver enzymes CYP3A4 and CYP2C19, and is a substrate for 
glucuronidation by UGT2B7.  Gemcitabine is metabolised by cytidine deaminase and is 
primarily eliminated in urine along with its metabolite difluorodeoxyuridine.  As expected 
from these distinct metabolic and elimination pathways, no pharmacokinetic interactions 
were observed; refametinib and gemcitabine exposures were comparable when administered 
alone or in combination. 
Overall, refametinib combined with gemcitabine is well tolerated in 8-weekly cycles up to the 
maximum tolerated dose, with no pharmacokinetic interaction.  The primary end point of 
phase II was met: the combination showed a relatively high ORR in patients with advanced 
pancreatic cancer, with an acceptable safety profile.  There was a trend towards improved 
survival in patients without detectable KRAS mutations compared with those with detectable 
KRAS mutations in circulating tumour DNA.  This study also suggests that biomarker status 
in patients with KRAS mutations may provide predictive or prognostic information with 
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Titles and legends to figures 
Figure 1.  Overall median PFS (A) and overall median OS (B) (primary analysis set).  
Abbreviation: CI = confidence interval. 
Figure 2.  Tumour response and mutant allele frequency (primary analysis set). 
Figure 3.  Change from baseline in target lesion size by KRAS mutational status (A), median 
PFS in KRAS subgroups (B) and median OS in KRAS subgroups (C) (primary analysis set).  
Nine out of the 60 patients in the primary analysis set were not evaluated for change in target 
lesion size, of whom two experienced protocol deviations.  Six patients were not evaluable 
for change in carbohydrate antigen 19-9 from baseline.  Abbreviations: CI = confidence 
interval; HR = hazard ratio; NE = not evaluable. 
